<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111536</url>
  </required_header>
  <id_info>
    <org_study_id>833681p</org_study_id>
    <secondary_id>1R61HL146390-01</secondary_id>
    <nct_id>NCT04111536</nct_id>
  </id_info>
  <brief_title>Developing Oral LT3 Therapy for Heart Failure - HFpEF</brief_title>
  <acronym>DOT3HF-HFpEF</acronym>
  <official_title>Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy
      with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction
      (HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind,
      placebo-controlled cross-over study with a two-week washout period between treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal is to determine the safety, feasibility, and preliminary efficacy of
      administering oral LT3 therapy in the study population of participants with Heart Failure
      with preserved ejection fraction (HFpEF). Each treatment period will be approximately 8 weeks
      in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose
      for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug). LT3
      will be titrated to T3 levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigators and Care Providers are blinded to LT3 vs. Placebo and T3 results. There will be 1 unblinded physician in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment</measure>
    <time_frame>continuous during intervention (14 days)</time_frame>
    <description>Percent increase (atrial fibrillation, ventricular tachycardia, supraventricular and ventricular) ectopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T3 Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of participant T3 levels above upper limit of reference range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change peak rate of oxygen consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change Kansas City Cardiomyopathy Questionnaire, KCCQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in remotely sensed difference in counts per minute (CPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP Levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in B-type natriuretic peptide, Pg/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Low Triiodothyronine Syndrome</condition>
  <arm_group>
    <arm_group_label>Liothyronine (LT3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liothyronine or placebo</intervention_name>
    <description>Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.</description>
    <arm_group_label>Liothyronine (LT3)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LT3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women aged ≥18 years; NYHA Class I, II or III heart failure or dyspnea on exertion
        without a clinically identifiable alternative cause; left ventricular ejection fraction
        greater than or equal to 50 percent; taking stable doses of antihypertensive medications
        and beta-blockers in the preceding 30 days. Elevated filling pressures as evidenced by at
        least 1 of the following:

          1. Mitral E/e' ratio &gt; 14 (either lateral or septal)

          2. Mitral E/e' ratio &gt; 9 (either lateral or septal), with low e' velocity (septal e'&lt;7
             cm/sec or lateral e'&lt; 10 cm/sec), in addition to one of the following:

               1. Enlarged left atrium (LA volume index &gt;34 ml/m2)

               2. Chronic loop diuretic use for control of symptoms

               3. Elevated natriuretic peptides (BNP levels &gt;100 ng/L or NT-proBNP levels &gt;300
                  ng/L)

               4. Tricuspid regurgitation velocity &gt;2.8 m/s

          3. Elevated invasively-determined filling pressures previously (resting LVEDP &gt;16 mmHg or
             mean pulmonary capillary wedge pressure [PCWP] &gt;12 mmHg; or PCWP/LVEDP ≥25 mmHg with
             exercise)

          4. Acute heart failure decompensation with radiographic evidence of pulmonary venous
             congestion or alveolar edema, requiring IV diuretics within the past year TSH and free
             T4 level within the laboratory reference range and total T3 level less than 94 ng/dL;
             if taking oral estrogen, dose must remain stable for duration of study participation.

        Exclusion Criteria:

        Hypertrophic or restrictive cardiomyopathy or uncorrected severe primary valvular disease;
        arrhythmia that results in irregular heart rate; inability to perform VO2max exercise
        testing; severe lung disease; treatment with oral steroids within past 6 months for an
        exacerbation of obstructive lung disease, or the use of daytime oxygen; serum creatinine &gt;
        3.0 mg/dL; history of cirrhosis; acute coronary syndrome or coronary artery intervention or
        ablation therapy within past 2 months; cardiac surgery or percutaneous valve or septal
        defect repair within the past 6 months; heart failure hospitalization within past month;
        taking thyroid extract, LT4, LT3, amiodarone, or medication that affects the absorption or
        metabolism of thyroid hormone; gastrointestinal conditions that affect the absorption of
        thyroid hormone; if female, current or planned pregnancy within the timeframe of study
        participation; any medical condition that, in the opinion of the investigator, will
        interfere with safe completion of the study.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R Cappola, MD,ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa M Scattergood, MSN</last_name>
    <phone>215-898-5664</phone>
    <email>theresa.scattergood@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne C Holland, BA</last_name>
    <phone>215-573-0902</phone>
    <email>anne.holland@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa M Scattergood, M.S.N., R.N.</last_name>
      <phone>215-898-5664</phone>
      <email>theresa.scattergood@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Annie C Holland, BA</last_name>
      <phone>215-573-0902</phone>
      <email>anne.holland@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Anne Cappola</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure, HFpEF, Low T3 Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

